Would be nice but it needs a catalyst. Of course, in biotech, a catalyst can move this to $25 in an hour.
You need to seriously look into PennyStock101 (org)...they have been delivering winner after winner for me and its nasdaq/nyse picks too. The free newsletter seems so far. Check them out now.
I am looking at initiating a position in ANTH and I looked at Yahoo Finance for some data. The salary for the CEO is listed as $916k, and two other execs at over $400k. If this is accurate, how is it reasonable with no products on the market, no revenue, and the need to conserve cash for clinical trials.
Looking for breaking otcmarket, nasdaq and nyse alerts. Check out PennyStock101 (org)! Google them... They have the best free stock newsletter. They always alertthe top gainers before the crowd.
NeuVax elicits CD 8 T Cells that hunt and kill Her2 Breast Cancer cells. Landmark 5 year Phase 2 data proved 78% overall RRR (relative recurrence reduction) and 100% DFS among Max Dosed Boosted at 36 Months.
Over 25% of all Her2 Node positive patients suffer a recurrence after chemo/radiation/surgery. Neuvax Saved 78.8% of the P2 Patients.
On August 14, 2015, Anthera Pharmaceuticals, Inc. (the "Company") entered into a Subscription Agreement (the "Subscription Agreement") with Zenyaku Kogyo Co., Ltd. ("Zenyaku") with respect to a registered direct offering conducted without an underwriter or placement agent (the "Registered Direct Offering") of an aggregate of 150,915 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), at an aggregate purchase price of $2,000,000. Pursuant to the Subscription Agreement, Zenyaku will purchase 150,915 shares of Common Stock at a price per share equal to $13.2525.
Sentiment: Strong Sell